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Naturally occurring regulatory T cells (Tregs) play a pivotal role in the maintenance of self-tolerance due to their
intrinsic immunosuppressive activity. Currently, a number of human clinical trials are being conducted to investigate
the roles of Tregs in treating various immune-mediated disorders. Traditionally, the suppressive activity of Tregs is
measured using either a thymidine incorporation assay, which is a radioactive assay; or CFSE based flow cytometry
assay, which requires a relatively large number of cells. Consequently, there is an increasing need to develop novel
alternative bioassays that can characterize various aspects of the immunosuppressive function of Tregs in vitro. In
this study, using murine clonal CD8+ T cells specific for an islet antigen as responder T cells, we first established a
novel, sensitive and quantitative in vitro luminescence based cell viability assay to measure cytotoxicity. Then we
used this assay to measure if Tregs could inhibit the cytotoxicity of CD8 effector T cells. This assay does not involve
the use of radioisotopes and only needs relatively low number of Tregs. Since normally Tregs only constitute 5-10% of
peripheral CD4+ T cells, this advantage is noteworthy compared with other methods. With the assay we developed,
we demonstrated that regulatory T cells (Tregs) could inhibit the antigen-specific killing of an adherent target cell
monolayer by the CD8+ cytotoxic T cells. We observed more inhibition when Tregs and CD8 killer T cells were
incubated during the in vitro activation (stimulation) stage of the cytotoxic T lymphocytes (CTL) than when they
were added later at the start of the effector phase. Interestingly, Tregs from B6 mice demonstrated higher suppression
of CD8+ T cell killing than Tregs from NOD mice. Moreover, IL-2/anti-IL-2 mAb complexes induced expansion of Tregs
in vivo, as well as enhancing the Treg’s suppressive activity per cell.
Therefore, this novel non-radioactive, luminescence based cytotoxicity assay mediated by clonal islet antigen-specific
CD8 T cells can be used to measure, characterize, and quantitate the immunosuppressive activity of natural Tregs,
representing a useful approach to characterize the functions of Tregs in the setting of autoimmune diseases and to
elucidate the mechanisms for Treg cell-mediated immunoregulation.
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Naturally occurring regulatory T cells (Tregs), are
CD4+CD25+Foxp3+ T cells capable of inhibiting the
function of effector T cells to regulate immunological
homeostasis [1]. Based on their tissue origin and differen-
tiation, Tregs can be divided into thymus-derived natural
Tregs (nTreg) and peripherally induced Tregs (iTregs).* Correspondence: chenghong.wei@fda.hhs.gov
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unless otherwise stated.There is a large amount of evidence for the role of
CD4+CD25+ Tregs in the maintenance of self-tolerance.
If Treg cells are artificially depleted, the result is lym-
phoproliferative disease resulting in death [2]. In Scurfy
mice the Foxp3 gene is mutated, inactivating their Tregs
and resulting in severe autoimmunity that affects multiple
organs [3]. In humans, similarly, mutation and loss of
function of Foxp3 leads to a decrease in regulatory T cell
number and function, leading to the severe multi-organ
autoimmune disease IPEX (immune dysregulation, poly-
endocrinopathy, enteropathy, and X-linked inheritance)
and death [4,5]. Based on these observations, several studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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promising immunotherapy of autoimmune diseases in
mice. For instance, it has been reported that adoptively
transferred Tregs can ameliorate the development of
autoimmune diseases in several murine models, including
type 1 diabetes [6,7], EAE (experimental autoimmune
encephalomyelitis) [8,9], colitis [10,11], arthritis [12],
and lupus [13].
In regards to autoimmune type 1 diabetes (T1D) in
which insulin-producing beta cells are destroyed by auto-
reactive T cells, many studies have investigated the role of
CD4+CD25+ Treg cells in regulating the onset and pro-
gression of the disease [14,15]. These studies have demon-
strated that supplementation of the endogenous CD4+
CD25+ Treg cell population provides resistance to the dis-
ease, whereas depletion of Treg cells accelerates T1D pro-
gression, showing that CD4+Foxp3+ Treg cells are critical
in the control of T1D in mouse models.
As reviewed by Buckner [16], Treg cell defects can lead
to autoimmune diseases. Defects include: decreased
number of Treg cells due to poor proliferation, survival
or stability; defects in Treg cell function (such as failed
contact-dependent suppression, decreased secretion of
soluble factors such as IL-10, TGF-β); and resistance of
effector T cells to the suppression by Treg cells. In non-
obese diabetic (NOD) mice (a model of spontaneous type
1 diabetes), Treg cell numbers and Foxp3 expression
decrease with the age of the animals [17], Treg function
also declines with aging of the NOD mice [18], although
there were also studies where decrease of Treg frequencies
was not discovered [19,20]. Adoptive transfer of Treg cells
can ameliorate disease in NOD mice [6], but over time the
pathogenic effector T cells in the pancreatic islets become
resistant to suppression [21-23]. All these studies have
confirmed the important role of Treg cells in the control of
diabetes onset and progression, and that a decrease in CD4
+Foxp3+ Treg cell frequencies or function in NOD mice,
constitutes a critical predisposing factor to T1D [15].
In order to examine whether there is a defect or ab-
normality in Treg function in certain human immune dis-
eases, sensitive and quantitative in vitro assays are needed.
Various kinds of suppression assays have been developed
to measure the suppression of responder T cell function
by Tregs. For example, the thymidine incorporation assay
has been used most frequently, in which suppression of
anti-CD3 mAb stimulated proliferation of CD4+CD25− T
cells (conventional T cells, Tconv) is measured by [3H]
thymidine incorporation [24,25]. The shortcoming of this
assay is that it cannot distinguish which specific cell popu-
lation in the co-culture has incorporated [3H] thymidine.
Needless to say, a radioactive isotope is used in this assay.
Another commonly used method is the CFSE-based cell
proliferation assay using FACS. It is similar to the [3H]
based assay in that this assay also measures proliferation,but the proliferation of CD4+CD25− T cells is measured
by the decrease of green fluorescence from CFSE dye
when cells divide [26]. The advantages of this method are
that it can specifically evaluate the proliferation of the re-
sponder T cell population (can be CD4 or CD8 T cell sub-
sets), as well as to examine the number of cell divisions
throughout the culture period [27]. However, the limita-
tion of CFSE dilution assays is that they require a larger
number of Tregs than [3H] thymidine incorporation assay.
Besides these methods, two other methods have also
been reported. One is a cytokine production assay, in
which the ability of Treg cells to inhibit the production of
cytokines by conventional T cells stimulated with anti-
CD3 mAb is measured [28]. Another assay is based on the
measurement of surface markers, for example, it has been
reported that Treg function can be quantified through
measuring their suppression of up-regulation of surface
markers (such as CD154, CD69) on Tconv following acti-
vation [29].
All of these methods have been commonly utilized by
different labs and provided very useful information for our
understanding of Treg cells. It needs to be noted, however,
that in most if not all cases, naïve non-antigen specific T
cells were used as the responder population, and anti-CD3
mAb was used for activation. Thus there is a lack of a
functional test on regulatory T cells’ function in regulating
antigen specific T cells. This issue is particularly relevant
for studies aiming at suppressing pathogenic auto-reactive
effector T cells, such as T cells specific for self-tissue anti-
gens (for instance, islet antigens, myelin basic protein-
derived antigens, thyroid antigens). As documented in the
literature, immune rejection and autoimmune responses
to islet antigens have been a major hurdle to achieving
long term engraftment of islet transplants [30], and even
genetically engineered insulin-producing cells cannot es-
cape from this kind of autoimmune attack [31]. Tregs
which can suppress this type of autoimmune responses
provide an alternative for immunotherapy to improve the
long-term survival of islets without depending on long-
term immunosuppressive drugs.
To address this specific need, in this study we have de-
veloped a novel, sensitive and quantitative luminescence
based assay that does not involve the use of radioactive
isotope, uses relatively low number of Treg cells, and can
be easily modified to a high-throughput format for screen-
ing purposes. In addition, islet-antigen specific CD8 T cells
were exploited as responder T cells, and antigen-specific
lysis of islet cells was used as a readout to measure the in-
hibitory function of Treg cells.
Materials and Methods
Ethics statement
All animal protocols and procedures were approved by the
Institutional Animal Care and Use Committees (IACUC)
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(CBER) and performed in animal facilities accredited by
the Association for Assessment and Accreditation of La-
boratory Animal Care International. All experiments were
performed according to institutional guidelines.
Cell culture
The insulinoma cell line NIT-1 (ATCC#CRL-205) estab-
lished from the islet beta cells of SV40 large T antigen
transgenic NOD mice [32], the fibroblast cell line NIH
3T3(ATCC#CRL-1658), and the BALB/c derived fibro-
blast cell line BALB/3T12-3 (ATCC# CCL-164) were all
purchased from American Type Culture Collection
(ATCC) (Manassas, VA) at passage one. NIT-1 cells were
cultured in T175 flasks, expanded in RPMI-1640
medium supplemented with 10% FBS, penicillin, strepto-
mycin and L-glutamine, and cultured at 37°C and 5%
CO2. NIH-3T3 cells and BALB/3T12-3 cells were grown
in DMEM and harvested with 0.25% Trypsin (Life Tech-
nologies, Grand Island, NY). NIT-1, NIH-3T3, and
BALB/3T12-3 were used at passage numbers of P2 –
P40. When performing sub-culturing, the cell surface
was rinsed twice with 2 ml of cell dissociation buffer
(Life Technologies, Grand Island, NY) or Trypsin, and
then incubated for approximately 6–8 minutes until cells
were detached. Subsequently, 3 ml of cell culture media
was added to the flask and cells were split at the desired
ratios. During the assay, cell density and viability were
determined using the Cellometer®Vision (Nexcelom Bio-
science, Lawrence MA). To perform the experiments,
the cell density was adjusted to 2000/50 μl in each test-
ing well, equal to 4x104 cells/ml. At this concentration,
50 μl cell suspension was added to the inner 60 wells of
a 96-well tissue-culture treated plate for a final density
of 2,000 cells/well. The tissue culture treated white
plates used in the assay (Corning Costar, Cat. #: 3917)
were made of polystyrene with white wall and flat and
white bottom.
Mice
NOD/ShiLtj mice, Nonobese diabetic 8.3 TCR trans-
genic mice (NOD 8.3) [33] were purchased from Jackson
Laboratories (Bar Harbor, Maine) and were maintained
in specific pathogen-free conditions. The 8.3 TCR trans-
genic CD8+ T cells specifically recognize the Kd-
restricted IGRP 206–214 epitope derived from the islet
antigen IGRP (islet-specific glucose-6-phosphatase cata-
lytic subunit-related protein) [34].
Peptide
The peptides IGRP 206–214 (VYLKTNVFL) and H-2K
d-
binding peptide Tum (KYQAVTTTL) were synthesized
and HPLC purified by FDA core facility. Purified IGRPand TUM were diluted to 10 mg/ml with DMSO and
stored at −20°C.
Flow cytometry analysis
Cells were incubated with antibodies at the optimized con-
centrations for 30 minutes at 4°C. The samples were cen-
trifuged, washed twice with PBS/1% fetal bovine serum,
and analyzed using a FACSCanto (Becton Dickinson)
flow cytometer. For flow cytometry analysis of regu-
latory T cells, anti-CD4, anti-CD8, anti-CD25, anti-
GITR, anti-CD62L, and anti-Foxp3 antibodies in various
fluorochrome combinations were purchased from BD
Biosciences (San Diego, CA).
Isolation and purification of CD4+CD25+ Tregs
Lymphocytes were obtained from the lymph nodes and
spleens of NOD or B6 mice treated with or without IL-
2/anti-IL-2 mAb complexes. CD4+CD25+ Tregs were
isolated using a Treg isolation kit (Miltenyi Biotech, Au-
burn, CA). Briefly, CD4+ T cells were first negatively se-
lected on a separation column, then the CD4+CD25+
and CD4+CD25− subsets were purified using PE-anti-
CD25 antibody and anti-PE magnetic beads (Miltenyi
Biotech, Auburn, CA) according to the manufacturer's
instructions. The purity of CD4+CD25+ regulatory cell
was consistently higher than 90%, as confirmed by
FACS.
Cytotoxicity assay as measured by CellTiter-Glo® (CTG)
method
The CTG based cytotoxicity assay is designed to deter-
mine the number of viable cells left in the culture as
a result of cytotoxic T lymphocyte killing of the target
cells. The assay involves the luciferase reaction, in
which mono-oxygenation of luciferin is catalyzed by the
UltraGloTM recombinant luciferase in the presence of
Mg2+, molecular oxygen, and ATP stemming from the
lysates of viable cells. As a result of the reaction, a lumi-
nescent signal defined as a relative luminescent unit
(RLU) is generated, which is proportional to the amount
of ATP present. The amount of ATP is directly propor-
tional to the number of metabolically active cells. A dir-
ect relationship exists between the luminescent signal
and the number of viable cells in culture. The lower the
number of viable cells associates with the strong killing
capacity of effector CD8+ T cells.
In the assay, lymphocytes were obtained from the
lymph nodes and spleens of NOD 8.3 TCR transgenic
mice. The CD8+ T cells were isolated using a mouse
CD8+ T cell isolation kit (Miltenyi Biotech). After isola-
tion, 2x106 CD8+ 8.3 T cells were seeded into a 24-well
plate, stimulated with anti-CD3/CD28 Ab conjugated
beads (Life Technologies, Grand Island, NY) at a bead to
cell ratio of 2 to 1 in the presence of 2000 IU/ml of
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RPMI 1640 medium (2 ml/well) for 3 days in a CO2 in-
cubator. Then magnetic beads were removed using a
DynaMagTM-2 Magnet (Life Technologies). Subse-
quently the in vitro activated 8.3 T cells were counted
and applied as the effector cytotoxic T cells in the CTG
assay to detect their killing capacities over the NIT-1
target cells. To set up an assay plate, 50 μl of NIT-1
cells were seeded into a 96-well white plates at indi-
cated concentration (2,000 cells/well unless specified
otherwise), and in vitro activated 8.3 T cells were added
to each well at the indicated effector cell (8.3 T cells) to
target cell (NIT-1 cells) ratio of 5:1. Simultaneously,
IGRP peptide was added to each well at a final concen-
tration of 20 μg/ml. After the overnight incubation
(12–16 hours), suspension T cells (both 8.3 T cells and
Tregs) were removed by three repetitive pipetting and
washing with cell culture media. The luminescent sig-
nal (relative luminescent unit, RLU) from a 96-well
plate was measured by the addition of 200 μl of 50%
Cell Titer Glo (Promega, Madison, WI) followed by
measurement of luminescent signals using a GloMax
multi-detection system (Promega, Madison, WI). The %
killing of the NIT-1 cells by 8.3 CD8+ T cells was calcu-
lated according to the following equation: % Killing =
100% x (RLU of untreated NIT-1 cells – RLU of NIT-1
cells cultured with 8.3 CD8+ T cells)/RLU of untreated
NIT-1.
Preparation of murine IL-2/anti-IL-2 mAb complexes
1 μg of murine IL-2 (PeproTech, Cat.#: 212–12) was in-
cubated with 5 μg of anti-mouse IL-2 mAb (eBioscience,
Clone: JES6-1, Cat.#: 16-7022-85; San Diego, CA) at 4°C
for 15 min to allow the formation of immune com-
plexes. Subsequently, the complexes of murine IL-2/
anti-mouse IL-2 mAb were injected into mice via i.p.
route in 100 μl HBSS to each recipient NOD mouse for
3 days (1 dose/day).
Testing the immunosuppressive activity of Tregs on CD8+
T cell cytotoxicity during the activation phase
NOD mice were treated with IL-2/anti-IL2 mAb com-
plexes (i.p.) on day 0, 1, and 2. On day 5, CD4+CD25+
Tregs were isolated from the untreated NOD or IL-2/
anti-IL-2 mAb complexes treated NOD mice. To inves-
tigate the role of Tregs during the activation phase,
freshly isolated Tregs and 8.3 CD8 T cells were cultured
together in the presence of the anti-CD3/anti-CD28 Ab
conjugated Dynabeads and human IL-2 for 3–4 days.
On the day of assay (the last day of activation of CD8 T
cells), CD8 T cells were separated from Treg cells by
negative selection using the mouse Dynabeads CD4
(L3T4) from Invitrogen. The NIT-1 cells were adjusted
to 2000/well. The 8.3 CD8 T cells were used at an E/Tratio of 5:1. The 8.3 CD8+ T cells and NIT-1 cells plus
IGRP peptide were mixed together and incubated over-
night. After overnight incubation, 8.3 T cells were ex-
cluded by washing three times with cell culture
medium while adherent NIT-1 cells remained in the
testing wells. Subsequently, the viability of NIT-1 cells
was measured by the addition of 200ul of 50% Cell
Titer Glo, which reflected the killing capacity of 8.3 T
cells over the NIT-1 cells.Testing the immunosuppressive activity of Treg on CD8 T
Cell Cytotoxicity during the effector phase
NOD or B6 mice were left untreated or treated with IL-
2/anti-IL2 mAb complexes (i.p.) on day 0, 1, and 2. On
day 2, TCR transgenic 8.3 CD8+ T cells were isolated
from the spleen/lymph nodes using CD8 T cell isolation
kit (Miltenyi) and activated in the presence of hIL-2
and CD3/CD28 Dynabeads for 3 days. On day 5, CD8+
8.3 T cells were separated from the beads with a Dyna-
MagTM-2 Magnet (Life Technologies), counted and re-
suspended in media. On the same day, CD4+CD25+
Tregs were isolated from the spleen/lymph nodes of
NOD or B6 mice treated with or without the IL-2/anti-
IL-2 mAb complexes, counted, and then mixed with
8.3 T cells and NIT-1 cells plus exogenous IGRP pep-
tide. A fixed number of NIT-1 cells (2000 cells/well)
and fixed E/T ratio of 5:1 (5 8.3 CD8+ T cells to 1 NIT-
1 cell) were used, and titrated number of Tregs was
added to obtain different ratios of Tregs to 8.3 T cells.
After 12 to 16 hours of incubation, the viability of NIT-
1 cells was measured by the addition of 200ul of 50%
Cell Titer Glo, which reflected the killing capacity of
8.3 T cells over the NIT-1 cells. The immunosuppres-
sive activity of Tregs was calculated as % inhibition of
killing.CFSE Immunosuppression assay
Spleens and lymph nodes were isolated from Thy1.1
NOD 8.3 TCR transgenic mice, then CD8+ T cells were
purified using the mouse CD8+ T cell isolation kit (Mil-
tenyi Biotech). 8.3 CD8+ T cells were labelled with CFSE
(InvitroGen, Carlsbad, CA) according to the manufac-
turer’s instructions, added to 24 well plates (Becton
Dickinson Labware, Franklin Lakes, NJ) (2 x 106 cells/
well). Subsequently anti-CD3/CD28 beads were added to
each well at the bead to T cell ratio of 2 to 1, and then
2x106 of CD4+CD25+ Tregs isolated from untreated or
IL-2/anti-IL-2 mAb complexes treated NOD mice were
added to the 24-wells plates where 8.3 CD8+ T cells were
seeded. The cells were kept in RPMI 1640 complete
medium (containing 10% FBS) in a 37°C incubator for
3 days after which T cells were harvested and stained
with anti-CD8 and anti-Thy1.1 Abs. CFSE dilution of
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flow cytometer.
Statistical Analysis
Data were analyzed using GraphPad Prism 5 software
(GraphPad, La Jolla, CA). The Student’s t test was used
to compare differences between pairs of samples and
groups. For comparison of 3 or more groups, one-way
ANOVA was used. The differences were considered
statistically significant when p value was below 0.05.
In figures, * indicates p < 0.05; ** p < 0.01; *** p < 0.001;
**** p < 0.0001.
Results
The kinetics of Cell Titer Glo (CTG) luminescent assay
using NIT-1 as target cells
The CTG assay is based on the Luciferase reaction. The
measurement of ATP through the luminescent signals
was used to reflect the number of viable cells. As
shown in Figure 1, when cell densities from 4x104 cells/
well down to 250 cells/well were used, the luminescent
signal could be detected, and there is a good linear cor-
relation between the RLU and the number of NIT-1
cells (R2 > 0.96, p < 0.0001). Following the addition of
CTG reagent, the incubation time could vary from
15 min to 5 hours, but signal at 20 hours dropped sig-
nificantly. Therefore, 30 minutes to 1 hour was used
most of the time in the process of assay development,
but the CTG incubation time could be up to 3 hours
occasionally if there were a large number of samples.
CTG assay can be used to detect killing of NIT-1 islet cells
by Ag-specific 8.3 T cells
We chose to use an adherent islet cell line (NIT-1) as
target cells. These cells can present the endogenously
processed islet antigen IGRP 206–214 peptide bound to K
d
molecules, thus are recognized and lysed by 8.3 CD8+ T
cells which bear the specific TCR recognizing this pep-
tide: MHC class I complex.
We tested the killing capacity of in vitro-activated
IGRP-specific CD8+ T cells (8.3 T cells). NIT-1 cells or
NIT-1 cells mixed with IGRP peptides were used as tar-
get cells. As shown in Figure 2A, at an E/T ratio of 10:1
(effector 8.3 T cells to target NIT-1 cells ratio), the islet
antigen (IGRP)-specific CD8+ 8.3 T cells killed about
15% of NIT-1 cells after the overnight (12–16 hours)
incubation. With the addition of exogenous IGRP pep-
tide, the killing was increased to 40%. Similarly, at
lower E/T ratio, 8.3 CD8+ T cells still killed the target
NIT-1 cells better when they were mixed with IGRP
peptide. Therefore, we chose to use NIT-1 cells to-
gether with addition of exogenous IGRP peptide
throughout our study.We also titrated the number of NIT-1 cells to see if
the target cell number per well had any impact on 8.3
killing capacity. As shown in Figure 2B, from 2x103 to
2x104 cells/well, at an E/T ratio of 5:1 (8.3 T cell: NIT
cell), the killing capacity remained comparable, ranging
around 40-60%. Also, throughout the whole study, the
killing is consistently 40 ~ 70%. Occasionally, the per-
centage of killing was even above 80%.
The cytotoxicity assay is antigen-specific
To verify the specificity of the CTG cytotoxic assay, the
cytotoxic activity of 8.3 CD8+ T cells was examined
with MHC-matched or non-matched target cells bear-
ing the cognate peptide or an irrelevant peptide. As
shown in Figure 3, although 8.3 CD8+ T cells were acti-
vated in vitro with anti-CD3/CD28 beads, if the NIT-1
cells were mixed with a control irrelevant TUM peptide
(Figure 3A), the killing was the same as those without
IGRP peptide (but since these are islet cells, they still
have endogenous Kd/IGRP complexes on their cell sur-
face, thus there was still a small percentage of killing
indicated by a decrease of RLU). More importantly, as a
control, fibroblasts from BALB/c mice were tested as
target cells, since these cells express the correct MHC
class I molecule Kd, when they were mixed with Kd-
presented IGRP peptide (the cognate peptide antigen
recognized by 8.3 TCR), they could be killed by acti-
vated 8.3 T cells efficiently (~50% lysis), while the same
APCs pulsed with a control irrelevant peptide (TUM)
could not be killed by activated 8.3 T cells (Figure 3B).
Similarly, activated 8.3 T cells did not lyse NIH3T3 cells
which are of the H-2q haplotype, whether these cells
were mixed with IGRP peptide or not (Figure 3C). All
of these data confirmed that the killing of IGRP peptide
pulsed NIT-1 cells was strictly dependent on the anti-
gen specific 8.3 TCRs which recognize the correct
IGRP/Kd complex on the target cell surface.
IL-2/IL-2 mAb complexes efficiently expanded
endogenous Treg cells in both B6 and NOD mice
It has been reported that the IL-2/anti-IL-2 mAb
(Clone: JES6-1) complexes can significantly expand
regulatory T cells in vivo without affecting other sub-
sets of immune cells [35]. We therefore administered
the same IL-2/anti-IL2 mAb complexes in vivo in both
B6 mice and NOD mice and followed the number and
function of Tregs. As shown in Figure 4A and B, the
administration of the IL-2/anti-IL-2 mAb complexes
significantly increased the percentage of CD4+Foxp3+
Treg cells both in spleen and pancreatic lymph nodes.
In the spleen, the NOD Tregs and B6 Tregs expanded
to a similar degree; however, in the pancreatic lymph
nodes, the expansion of B6 Tregs was significantly
higher than that of NOD Tregs. When the expression
Figure 1 Variation of signals in CTG method for different numbers of NIT-1 target cells and different incubation times. (A) NIT-1 cells
were cultured in RPMI medium until 80-90% confluent and then detached with cell dissociation buffer to count for use in the assay. Cells at an initial
density of 4 x 104 cells/well (50 μl) were titrated in 2-fold steps in a 100 μl volume per testing well. After overnight culture, the cells were washed, CTG
reagent was added, and relative luminescence units (RLU) were measured at the various time points (A). The same procedure was used with lower
NIT-1 cell numbers (B). The data shown are the mean and SD of triplicates and the results are representative of three independent experiments. For
panel A, R2 is >0.98 for all curves (p < 0.0001); for panel B, R2 is >0.96 for all curves (p < 0.0001).
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was clear that the IL-2 complexes treatment signifi-
cantly enhanced the expression of both Treg markers,
and there was no significant difference between the
treated B6 and NOD group (n = 4/group).
Also, we checked the purity of freshly isolated Treg
by staining with anti-CD4 and anti-CD25 antibodies
and flow cytometry. As shown in Additional file 1: Figure
S1A, the purity of isolated Tregs was well above 95%.
And the majority of the Tregs expressed Foxp3 andGITR, two hallmark molecules that are defined as the
signature markers of Tregs (Additional file 1: Figure
S1B).
Inhibitory activity of Treg cells from NOD and B6 mice at
the effector phase
It has been reported that Treg cells from NOD mice have
reduced capacity to inhibit Tconv [18]. Therefore, we
measured the inhibitory activity of Treg cells from NOD
mice and B6 mice at the effector phase of 8.3 CD8+ T cells
( i.e. the 8.3 CD8+ T cells had already been activated with
Figure 2 Killing of NIT-1 islet cells by islet antigen specific 8.3 CD8+ T cells in the absence or presence of exogenous IGRP peptide. (A)
The killing capacity of in vitro-activated IGRP-specific CD8+ 8.3 T cells was tested. NIT-1 cells or NIT-1 cells plus IGRP peptide at 20ug/ml
(final concentration) were used as target cells. NIT-1 cells at the density of 2x103 cells/well (50ul), equal to 4x104 cells/ml, were prepared
initially. Effector/Target cell (CD8 8.3 T cells/NIT-1) ratios of 10/1, 5/1, 2/1, and 1/1 were used in a final volume of 200 μl per well. After
overnight incubation, 8.3 T cells were removed by washing three times with cell culture medium while adherent NIT-1 cells remained in
the testing wells. Subsequently, the ATP contents reflecting the NIT-1 cell remaining viable were measured by the addition of 200 μl of
50% Cell Titer Glo followed by measurement of luminescent signals on a GloMax multi-detection system (Promega). Cytotoxicity (% killing
of NIT-1 cells) was calculated as described in the material and method. Shown are mean and SD of 10 replicates for each sample. *p < 0.05; **p < 0.01
(t-test). The data are the representative of three experiments. (B) Based on Figure 1, the numbers of NIT-1 cells were selected for testing in the cytotoxicity
assay. NIT-1 cells at 2x103/well, 5x103/well, 1x104/well, and 2x104/well were tested with the E/T ratio of 5/1. After overnight incubation, 8.3 CD8+ T cells were
removed by washing three times with cell culture medium while adherent NIT-1 cells remained in the testing wells. Subsequently, cytotoxicity (% killing of
NIT-1 cells) was measured and calculated as described in the materials and methods. Shown are the mean and SD of 10 replicates for each sample. The
results are the representative of three experiments.
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Figure 3 The killing of NIT-1 islet cells was dependent on the
specific recognition of the IGRP peptide/MHC I Kd complex by
8.3 TCR. (A) To verify that the cytotoxic assay is dependent on the 8.3
TCR’s specific recognition of its ligand (i.e. the IGRP peptide/Kd complex),
a control peptide, TUM (aa sequence KYQAVTTTL) was included in
parallel to IGRP; both IGRP and TUM at 20 ug/ml were tested. And NIT-1
cells at 2x103/well and an E/T ratio of 5/1 were used in the assay. (B)
BALB/3T12-3, a mouse fibroblast cell line derived from BALB/c mice and
thus has the correct allele (Kd), was also tested with the addition of
exogenous IGRP peptide or the control TUM peptide. (C) In
addition, the NIH3T3 cells, a mouse fibroblast that lacks expression
of Kd/IGRP, was tested in the same conditions as NIT1 cells. After
overnight incubation, 8.3 CD8+ T cells were removed by washing
three times with cell culture medium while the adherent NIT-1 or
fibroblast cells remained in the testing wells. Subsequently, 200 μl
of 50% Cell Titer Glo was added to each well followed by measurement
of luminescent signals on a luminometer, and the % killing was
calculated based on the RLU measured. The data shown are the
representative of three experiments.
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ated into cytotoxic T cells that were immediately ready
to kill their target cells). 8.3 T cells were in vitro acti-
vated for 3 days, then mixed with Treg cells at various
ratios. The mixture of 8.3 CD8+ T cells and Tregs was
added to NIT-1 cells and incubated overnight for 12–
16 hours. The suspended Treg cells and 8.3 T cells
were washed away by three repeated pipetting and
washing, while the adherent NIT-1 cells remained in
the well. The killing of NIT-1 cells by 8.3 T cells was
measured by the CTG assay. As shown in Figure 5A,
Tregs from NOD mice inhibited less than 10% of 8.3
killing; while Tregs from B6 mice had inhibitory activ-
ity of about 20%. With Treg cells isolated from IL-2/
anti-IL-2 mAb complexes treated NOD mice, the in-
hibitory activity increased to 40%. Similarly, the Tregs
isolated from B6 mice treated with IL-2/anti-IL-2 mAb
complexes had an inhibitory activity of more than 80%.
When Treg cells from B6 mice treated with IL-2/anti-
IL-2 mAb complexes were further titrated (Figure 5B), it
was clear that these Tregs had very potent inhibitory ac-
tivities. They could inhibit the killing of activated ef-
fector 8.3 T cells (that had been in vitro activated for
3 days) by 80% at Treg to 8.3 CD8 T cell ratio of 1 to 1
and 100% at Treg to 8.3 CD8 T cell ratio of 2 to 1. At
lower ratio (0.25:1 Treg to 8.3 T cells) the inhibition
dropped to 0%. Figure 5C showed the titration of Treg
cells from NOD mice treated with IL-2/anti-IL-2 mAb
complexes, they maintained higher suppressive activity
until 0.375/1 (Treg/8.3 CD8 T cell) ratio compared with
untreated Tregs (Figure 5A). In contrast to Tregs, when
varied numbers of CD4+CD25− Tconv cells were used as
control, there was no inhibition of killing at all ratios
(Additional file 2: Figure S2).
Figure 4 IL-2/anti-IL-2 mAb complexes significantly expand Tregs in both B6 and NOD mice. Female NOD mice and B6 mice (6–8 week
old, n = 4/group) were left untreated or treated with IL-2/anti-IL-2mAb. On day 5 cells were isolated from lymphoid organs and labeled with anti-
CD4, anti-CD8 and anti-CD25 antibodies then with anti-Foxp3 and anti-GITR antibodies and analyzed by FACS for % of Foxp3+ cells among CD4+
T cells in spleen and pancreatic lymph nodes (A-B), the MFI of GITR and Foxp3 on Tregs in different groups were also analyzed (C-D).
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activation (stimulation) phase
We next wanted to investigate whether 8.3 T cells’ kill-
ing capacity can be inhibited more efficiently if the Treg
cells were present during the activation phase (stimula-
tion phase) of 8.3 CD8+ T cells (i.e. during the 3-day ini-
tial activation period when naïve resting 8.3 CD8+ Tcells were stimulated with CD3/CD28 beads and hIL-2).
As expected, when naïve, unstimulated 8.3 CD8+ T cells
were mixed with NOD Treg cells during the activation
phase (in vitro activation with CD3/CD28 beads plus
hIL-2 for 3 days), 3 days later their killing capacity was
diminished by about 80% at the Treg/8.3 ratio of 1:1
(Figure 6A).
Figure 5 Inhibitory activity of Treg cells from NOD and B6 mice
at the effector phase. (A) IL-2/anti-IL-2mAb complexes enhanced
the immmunosuppressive activities of endogenous regulatory T-cells
at the effector phase. (B) Impact at the effector phase of varied
numbers of Treg cells isolated from B6 mice treated with IL-2/anti-IL-
2mAb complexes. (C) Impact at the effector phase of varied numbers
of Treg cells isolated from NOD treated with IL-2/IL-2mAb complex. 8.3
CD8 T cells were isolated from TCR transgenic 8.3 mice using the CD8+
T cell isolation kit from Miltenyi. They were then in vitro activated for
3 days with CD3/CD28 Dynabeads and human IL-2. On the day of the
assay, Treg cells from mice untreated or treated with IL-2/anti-IL-2mAb
complexes for 3 days (i.p) were isolated using the CD4+CD25+ Treg
isolation kit from Miltenyi. The 8.3 CD8 T cells activated in the
culture were separated from Dynabeads by magnet. NIT-1 cells
were plated at 2000/well (50 μl), equal to 4x104 cells/ml. 8.3 CD8+
T cells were used at an E/T ratio of 5:1. Various concentrations of
Treg were mixed with the 8.3 CD8+ T cells and then added to NIT-
1 cells. After overnight incubation, Treg cells and 8.3 CD8+ T cells
were removed by washing three times with cell culture medium
while adherent NIT-1 cells remained in the testing wells.
Subsequently, the viability of remaining NIT-1 cells was measured by
the addition of 200 μl of 50% Cell Titer Glo. Mean and SD of triplicate
samples were shown; and the data shown are representative of three
independent experiments.
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been treated with IL-2/anti-IL-2 mAb complexes, their
inhibitory activity during the activation phase did not
improve dramatically (Figure 6B). We speculate that
Tregs may have a maximal suppressive activity; IL-2/
anti-IL-2 mAb treatment may not be able to further im-
prove Treg’s inhibitory activity when Tregs were already
very potent during the stimulation phase. This
phenomenon and its mechanism need further investiga-
tion. Also, in direct contrast to CD4+CD25+ Tregs, CD4
+CD25− Tconv cells did not significantly inhibit 8.3 kill-
ing during the activation phase (data not shown).
IL-2/IL-2 mAb complexes efficiently enhanced the
immunosuppressive ability of Tregs
Besides testing the Treg’s function using the new
method developed here, we were also attempting to
measure the immunosuppressive activity of Tregs with
the commonly used CFSE assay. As shown in Figure 7,
IL-2/anti-IL-2 mAb treated NOD Tregs exhibited sig-
nificantly higher inhibition of conventional T cell prolif-
erations (in this case 8.3 CD8 T cells activated with
anti-CD3/anti-CD28 beads).
Treg cells inhibited the formation of clusters during the
activation phase of 8.3 CD8+ T cell activation
When 8.3 CD8+ T cells were resting, they were round
and small cells under the microscope. After activation
with the specific antigen-pulsed APCs, they formed large
clusters, a characteristic morphology of the activated ef-
fector T cells. However, if Tregs were present from the
beginning of the stimulation phase, the cluster formation
Figure 6 Inhibitory activity of Treg cells from untreated and IL-
2/anti-IL-2 mAb complexes treated NOD mice at the activation
phase. As described in the materials and methods, NOD mice were left
untreated or treated with IL-2/anti-IL-2 mAb complexes. To investigate
the role of Treg cells during the activation phase, freshly isolated Treg
cells and 8.3 CD8+ T cells were cultured together in the presence of
the anti-CD3/anti-CD28 Ab conjugated Dynabeads and human IL-2 for
3–4 days. On the day of assay (the last day of activation of CD8 T cells),
CD8+ T cells were separated from Treg cells by negative selection
using the mouse Dynabeads CD4 (L3T4) from Invitrogen. The NIT-1
cells were adjusted to 2000/well. The 8.3 CD8+ T cells were used at an
E/T ratio of 5:1. The 8.3 CD8+ T cells and NIT-1 cells plus IGRP peptide
were mixed together and incubated overnight (12 to 16 hours). After
overnight incubation, 8.3 T cells were excluded by washing three
times with cell culture medium while adherent NIT-1 cells
remained in the testing wells. Subsequently, ATP contents
reflecting the NIT-1 cell remaining viable was measured by the
addition of 200 μl of 50% Cell Titer Glo. The data shown are
representative of three experiments. (A) Tregs from untreated NOD
mice. (B) Similar to A, but Tregs were isolated from IL-2/anti-IL-2
mAb complexes treated NOD mice. Mean and SD of triplicate
samples were shown; and the data shown are representative of
three independent experiments.
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Tregs suppressed the activation of resting, islet antigen-
specific CD8 T cells. Additionally, we found that when
8.3 CD8+ T cells were activated with anti-CD3/anti-
CD28 beads, the presence of Tregs also inhibited the
formation of clusters (Additional file 3: Figure S3).
Discussion
In this study, we have developed a simple and standard-
ized in vitro bioassay to detect CD4+CD25+ Treg cell-
mediated suppression. The sensitive CellTiter-Glo®
(CTG) method was capable of measuring the Treg cell’s
capacity to inhibit CTL lysis of its specific target cells.
The assay was quantitative over a broad range of cell
numbers and worked at both effector and stimulation
phase during CD8 T cell activation.
We showed that Treg cells from untreated NOD had
minimal inhibitory activity during the effector phase.
However, Treg’s activity at this stage could be enhanced
by the IL-2/anti-IL-2 mAb treatment. Interestingly,
Tregs from untreated NOD mice had much greater in-
hibitory activity at the activation phase compared to that
at the effector phase of CD8 8.3 T cell differentiation.
Tregs from a different strain of mice (B6) on the other
hand demonstrated higher inhibitory activities than
NOD mice overall. This is consistent with the fact that
B6 Idd3 allele provides T1D resistance while NOD Idd3
confers susceptibility to T1D development [36]. It has
been hypothesized that IL-2 is one of the two key candi-
date genes in the Idd3 locus, because the presence of an
Idd3 susceptibility gene compared with the T1D resist-
ant allele results in lower expression of IL-2 [37], and
the lower expression of IL-2 can leads to T1D suscepti-
bility due to impaired function of Tregs [38].
The assay can be used to measure the suppressive activ-
ity of Treg on 8.3 CD8 T cells at both effector and activa-
tion phases. Different mechanisms of immunosuppression
are reported to be utilized by Tregs [39], and the mecha-
nisms might be different during the activation phase and
the effector phase of the conventional T cells. For instance,
the effector T cells may be killed by Tregs through gran-
zyme and perforin-mediated cytolysis [40,41]; while dur-
ing the activation phase, the Tregs may consume the IL-2
cytokine present in the environment and act as an IL-2
“sink” [42], or negatively regulate the interaction of Tconv
with DCs [43], thus preventing a productive, complete T
cell activation.
Interestingly, the cluster formation of activated 8.3 T
cells was inhibited by the presence of Tregs. This could
be due to the fact that Tregs constitutively express the
IL-2 receptor alpha chain (CD25), thus acting as a “sink”
for IL-2 that limits the activation of naïve 8.3 T cells.
Another possibility is that the expression of adhesion
molecules required for cluster formation following T cell
Figure 7 IL-2/anti-IL-2mAb complexes enhanced the inhibitory activity of Tregs in NOD mice as measured by CFSE assay. Female NOD
mice 6–8 week old were left untreated or treated with IL-2/anti-IL-2mAb. On day 5 cells were isolated from lymphoid organs, CD4+CD25+ Tregs
were purified from both groups, and co-cultured with equal number of CFSE-labelled CD8+Thy1.1+ 8,3 T cells in the presence of anti-CD3/anti-
CD28 beads (2:1 beads: cell ratio). 3 days later, cells were stained with antibodies (anti-CD4, anti-CD8, anti-Thy1.1), and analyzed on a flow
cytometer. The CFSE dilution (% proliferation) of 8.3 CD8+ T cells (gated on CD8, Thy1.1 double positive population) was plotted. Shown are the
data from one representative experiment out of two independent experiments with similar results.
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lated by Tregs. All these mechanisms need to be further
investigated.
Moreover, using the CTG assay as a platform, screen-
ing of chemicals such as VitD3, rapamycin, retinoic acid,
HDAC (histone deacetylase) inhibitors and cytokines(IL-10, TGF-β, IL-4 etc.) and various combination of
chemicals and cytokines for the most optimal condi-
tions of Treg expansion and culture can be achieved.
Even further, the in vitro findings can be correlated
with in vivo models (T1D model in NOD mice, skin
transplantation between allogeneic mice) to establish a
Figure 8 Treg cells inhibited the formation of clusters during
the activation phase of 8.3 CD8+ T cell activation. The figure
shows the bright field images (100X) of CD8+ 8.3 T cells un-stimulated
(A) or stimulated with specific IGRP peptide (B), or stimulated with
specific IGRP peptide in the presence of Tregs (C) for 72 hours.
Irradiated (3,000 Rad) splenocytes from NOD mice were used as APCs.
The results are the representative of 3 different individual experiments
with similar findings.
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mediated immunotherapies. Since the common interest
in Tregs as a candidate product to treat immune-
mediated diseases has increased over time, establishing
these animal models and understanding the immune
regulation mechanisms may be extremely helpful in
seeking new treatments for autoimmune diseases.
This new method has certain advantages over some
previously established methods for evaluating Treg func-
tions. The most commonly used technique to measure
Treg activity is to label the Tregs and the responder T
cells with [3H] thymidine and measure the incorpor-
ation. There are a number of disadvantages with this
method. A major shortcoming is the radioactive isotope
usages. Second, the assay usually needs more responder
cells and Tregs (usually from 5x104 to 5x105 cells).
Third, the labeling typically requires up to 18 hours of
incubation time. Another approach to evaluate Treg
function is CFSE labeling. This method requires larger
number of cells to be labeled (up to several millions).
Since Tregs only constitute 5 to 10% of CD4+ T cells in
peripheral blood, an assay that needs lower number of
Tregs will be ideal. In this study, we defined the broad
range of target cell numbers from several hundred up to
4x104 per testing well. And we only needed 104 Tregs/
well for the assay. On the other hand, there were pub-
lished examples of the CFSE assay being performed with
fewer cells in a 96 well plate format (such as using
2.5x104-105 cells per well) [22]. Even in this case, the ad-
vantage of the CTG assay is that it can measure the
suppression of effector function rather than only
proliferation.
Although in this study we used NIT-1 cells and 8.3 T
cells as target and effector cells, this method can be eas-
ily adapted and modified depending on what effector
cells and target cells are available. Other researchers can
establish their own system without NIT-1 cell or 8.3 T
cells. However, it should be noted that non-adherent
cells as target cells cannot be used in this method.
In this study, islet-antigen specific CD8 T cells were
used as the responder T cells, and antigen-specific lysis
of islet cells was used as the functional readout to be
inhibited by Treg cells. This has particular relevance
for Treg-related research focused on tolerance induc-
tion and prevention of diabetes without the use of
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severe long-term side effects, such as toxicity to the
transplanted islet cells, and increased susceptibility to
infections or cancers. The system could use human islet
antigen-specific T cells as responder cells, and is a ver-
satile platform for other studies if other self-tissue anti-
gen specific T cells (such as MBP-specific T cells,
insulin-specific T cells, thyroid antigen-specific T cells)
are used as responder T cells.
In sum, self-tissue antigen-specific clonal T cells can be
used to measure, characterize, and quantify the in vitro
immunosuppressive activity of regulatory T cells, repre-
senting a promising approach to evaluate the various as-
pects of Tregs in mediating immunosuppression.
Additional files
Additional file 1: Figure S1. Confirmation of the purity and surface
marker expression of purified Treg cells. FACS was performed on freshly
isolated CD4+CD25+ Treg samples or CD4+CD25− Tconv cells from
untreated NOD mice to evaluate their purity. (A) Expression of CD4 and
CD25 on the gated CD4+ cells. (B) Expression of Foxp3 and GITR on the
gated CD4+CD25+ Tregs. The results are the representative of three
experiments.
Additional file 2: Figure S2. Tconv did not inhibit the killing of NIT-1
by activated 8.3 CD8+ T cells. 8.3 CD8 T cells were isolated, in vitro
activated for 3 days with CD3/CD28 Dynabeads and human IL-2. On the
day of the assay, CD4+CD25− conventional T cells (Tconv) from mice
treated with IL-2/anti-IL-2mAb complexes for 3 days (i.p) were isolated
using the CD4+CD25+ Treg isolation kit from Miltenyi (take the CD4
+CD25− fraction that was not bound to the column). 8.3 CD8+ T cells
were used at an E/T ratio of 5:1. Various concentrations of Tconv were
mixed with the 8.3 CD8+ T cells and then added to NIT-1 cells. After
overnight incubation, cytotoxicity (% killing of NIT-1 cells) was measured
as described in the materials and methods. Mean and SD of 5 replicates
for each sample were shown.
Additional file 3: Figure S3. Treg cells inhibited the formation of
clusters during the activation phase of 8.3 CD8+ T cell stimulated with
CD3/CD28 beads. The figure shows the bright field images (100X) of CD8
+ 8.3 T cells stimulated with CD3/CD28 beads for 72 hours in the
absence (A) or presence of Tregs (1:1 Treg/8.3 ratio) from untreated NOD
mice (B). The results are the representative of 3 different individual
experiments with similar findings.
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